NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2017
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
6/8 — Strong
LYRICA CR (pregabalin) by Viatris is 2 ‑delta site (an auxiliary subunit of voltage‑gated calcium channels) in central nervous system tissues. First approved in 2017.
Drug data last refreshed 43m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYRICA CR is an extended-release oral formulation of pregabalin, a small-molecule pain and seizure medication that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. It reduces the release of pro-nociceptive neurotransmitters in the spinal cord and modulates pain transmission through descending noradrenergic and serotonergic pathways. The drug is indicated for neuropathic pain, fibromyalgia, and postherpetic neuralgia.
$0.4MPart D
LOE Approaching6mo to LOEProduct is nearing loss of exclusivity in 2027 with minimal current sales momentum, signaling a contracting brand team focused on transition strategy.
Mechanism of Action
2 ‑delta site (an auxiliary subunit of voltage‑gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin)…
Indications
Worked on LYRICA CR at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.